Skip to content
Screener

Simulations Plus SLP Commercialization — Revenue

Other product segments

Development
$17.07M+10.8%
Discovery
$2.48M-1.7%
Clinical Operations
$277K-33.4%

Similar metrics at other companies

Regeneron Pharmaceuticals logo
REGNReimbursement Of Commercialization Related Expenses — Revenue
$188.8M-2.7%
Ironwood Pharmaceuticals logo
IRWDCollaborative Arrangement Development And Commercialization Agreements — Revenue
$500K+119%
Glaukos logo
GKOSDevelopment And Commercialization Of Ophthalmic Therapies — Revenue
$185.61M+49.5%
Oracle logo
ORCLCloud Revenues — Revenue
$9.91B+47.1%
Oracle logo
ORCLSoftware Revenues — Revenue
$6.82B-2.1%
Blue Owl Capital logo
OWLPerformance revenues — Revenue
$6.07M-3.9%

Other financials

Income statement

See full
Revenue$21.9M+7.5%
Gross profit$15.1M+16.1%
Operating income$4.5M+106%
Net income$3.6M+105%
EPS (diluted)$0.18+105%

Balance sheet

See full
Cash & equivalents$35.3M+31.1%
Total debt$487.0K-32.3%
Total equity$139.0M+12.3%
Total assets$153.0M+13.9%

Cash flow

See full
Operating cash flow$8.7M+6.9%
CapEx$93.0K-68.7%
Free cash flow$8.6M+9.8%

Valuation

See full
Market cap$371.13M+32.9%
Enterprise value$336.29M+33.0%
P/E45.8×—
P/S4.5×+1.0×

Profitability

See full
Gross margin63.4%+9.6pp
Operating margin13.2%—
Net margin9.9%+5.2pp
FCF margin29.9%+12.8pp

Returns & leverage

See full
Return on equity6.2%+3.3pp
Debt / equity0×0.0×
Current ratio5.5×+0.4×

Where this comes from

Reported directly by Simulations Plus in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Simulations Plus’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:10 PM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q2 2026
Accession
0001023459-26-000038
(in thousands, except per common share and common share data)Three Months Ended / May 31, 2026Three Months Ended / May 31, 2025Nine Months Ended / May 31, 2026Nine Months Ended / May 31, 2025
Revenues
Software$12,608$12,615$36,126$36,814
Services9,2787,74828,47224,905
Total revenues21,88620,36364,59861,719
Cost of revenues
Software1,5132,5404,5737,765
Services5,2464,79117,86417,577
Total cost of revenues6,7597,33122,43725,342

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Simulations Plus's commercialization — revenue?
Simulations Plus (SLP) reported commercialization — revenue of $2.06M in Q1 2026.
How has Simulations Plus's commercialization — revenue changed year-over-year?
Simulations Plus's commercialization — revenue increased by 1.8% year-over-year, from $2.02M to $2.06M.
What does commercialization — revenue mean?
This metric represents the total revenue generated from the commercialization segment, which encompasses the sale of software products and associated consulting services for pharmaceutical research. It serves as a key indicator of the company's ability to monetize its intellectual property and research tools within the life sciences market. Tracking this revenue stream helps investors assess the growth trajectory and market adoption of the company's core software offerings.

Ask your AI about Simulations Plus's commercialization — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude